Vaxcyte, Inc. (PCVX) Balance Sheet

The balance sheet is weakening as cash reserves are consumed to fund clinical development, with total assets peaking at $3.6B in 2024Q3 before declining to $3.1B by 2026Q2. This trajectory suggests the company is in a pre-revenue phase, relying on equity raises to sustain operations, as evidenced by the equity base fluctuating around $2.8B to $3.4B. The increasing accumulated deficit, from -$1.0B to -$2.8B, indicates that losses are outpacing any asset growth, signaling a deteriorating financial position.

Despite the increase in debt, the D/E ratio remains minimal, suggesting that Vaxcyte is not heavily reliant on debt financing. However, the jump in debt from $71.1M in 2024Q4 to $228.8M in 2025Q4, followed by a drop to $115.4M, indicates possible short-term borrowing or convertible notes that may carry refinancing risk. Given the company's negative cash flow, investors should monitor the terms of this debt, as it could become a burden if cash reserves continue to deplete.

The significant increase in property, plant, and equipment suggests Vaxcyte is investing heavily in manufacturing capabilities, likely to support future commercialization. This asset-heavy shift is typical for a biotech scaling up production, but it also implies higher fixed costs and depreciation going forward. The absence of goodwill and intangibles indicates that growth has been organic, reducing the risk of impairment charges.

The equity base has been maintained through repeated equity offerings, as evidenced by the stable equity levels despite massive losses. However, the accumulated deficit is growing rapidly, and with no revenue, the company will likely need to raise additional capital, which could dilute existing shareholders. The reliance on equity financing rather than debt suggests that investors are funding the R&D pipeline, but this is not sustainable indefinitely.

The current ratio remains above 5, suggesting adequate short-term liquidity, but the trend is concerning as it has more than halved over the period. Cash burn is accelerating, with operating cash outflows exceeding $500M in recent quarters, implying that the current cash position may only cover a few quarters of operations. This underscores the urgency for additional funding or a successful product launch.